Researchers in Stanford University's EXtreme Environment Microsystems Laboratory (XLab) working in collaboration with the University of Arkansas' Mixed-Signal Computer-Aided Design (MSCAD) Laboratory developed a Hall-effect sensor design that detects ultra fast changes in the
Different drug delivery agents, including synthetic polymers, virus-based vectors, lipid-based vectors, and extracellular vesicles (EVs), have been explored previously.
Stanford scientists have developed a working model that chemotherapy drugs induce peripheral neuropathy by activating a pathway that favors neuronal degeneration and impairs sensory neuron function.
Stanford researchers have invented an efficient rotary actuator that recycles elastic energy by engaging and disengaging springs using concentric electroadhesive clutches.
Clinician-scientists at Stanford have proposed a WNT formulation that, when used in combination with a first-of-its-kind normothermic perfusion device, reconditions marginal organs and enables their safe transplantation.
Stanford researchers have developed a mechanistic guideline for lithium metal battery electrolyte and separator design to mitigate lithium dendrite growth.
Brief Description: Inventors at Stanford have developed a novel fiber-optic technology to achieve unprecedented sensitivity and immunity to motion artifacts that can be used in freely moving animals.
Inventors at Stanford have developed a novel strategy to perform concurrent fluorescence measurements of multiple biological parameters in freely moving and head-restrained animals.
Stanford scientists have discovered multiple functionally biased ligands that can selectively activate distinct subsets of signaling pathways downstream of the complement 5a receptor.
Researchers at Stanford have found that applying pressure to macroencapsulation can enhance insulin transport from encapsulated islet beta cells to surrounding tissue and assist in glucose metabolism in type 1 diabetes (T1D) patients.
Genome editing of human hematopoietic stem and progenitor cells (HSPCs) has the potential to create a new class of medication for the treatment of inherited and acquired genetic diseases of the blood and immune system.
Stanford researchers have identified an appropriate method and dosage for radiotherapy-based noninvasive lung volume reduction to treat severe emphysema.
Many applications in cell therapy, synthetic biology, and gene therapy require extensive cell engineering, often with multiple vectors due to limitations in packaging capacity.